Cosibelimab standard usage, dosage and injection cycle

As of July 2025, Cosibelimab (Cosibelimab, trade name: Unloxcyt) has not been approved for marketing in China and is mainly used for scientific research. The drug is an anti-PD-L1 monoclonal antibody developed by Checkpoint Therapeutics. It is mainly used to treat malignant tumors such as metastatic cutaneous squamous cell carcinoma (cSCC). At this time, details regarding its standard usage, dosage and injection cycle have not been made public. Therefore, no specific treatment options can be provided.

In the United States, clinical trial data of cosibelimab show that in patients with metastatic cutaneous squamous cell carcinoma, the use of cosibelimab at a dose of 800 mg once every two weeks has achieved significant efficacy. The study's primary endpoint was confirmed objective response rate (ORR), which was 47.4% and 76% whose duration of response had not yet reached the median. These data provide support for its potential use in this indication.

However, there is no published clinical data on the treatment of cosibelimab in other indications (such as non-small cell lung cancer, gastric cancer, etc.). Therefore, detailed information on its standard use, dosage, and injection cycle for these indications cannot be provided.

In conclusion, cosibelimab, as a new anti-PD-L1 monoclonal antibody, has shown good efficacy in the treatment of metastatic cutaneous squamous cell carcinoma. However, since it has not been approved for marketing in China and clinical data in other indications are limited, patients should be cautious when using this drug and under the guidance of a professional doctor.

Reference materials:https://www.drugs.com/